Gleacer solution for injection 250mg / ml, 4ml No. 3

- Traumatic brain injury with a predominantly stem level of the lesion (acute period)

- cerebrovascular insufficiency

- psychoorganic syndrome against the background of degenerative diseases and involutional processes of the brain

- multi-infarction dementia.

Intramuscularly or intravenously slowly at 1000 mg / day for 15-20 days.

For intravenous administration, the contents of one ampoule (4 ml) are diluted in saline.

Active substance:

Choline alfoscerate hydrate (in terms of anhydrous substance) - 250 mg

Excipient:

Water for injection - 1 ml

- Pregnancy breastfeeding

- hypersensitivity to drug components

- age up to 18 years

- hemorrhagic stroke (acute period).

Trade name of the drug

Gleazer

International non-proprietary name

Choline alfoscerate

Dosage form

solution for intravenous and intramuscular administration

Composition

Active substance:

Choline alfoscerate hydrate (in terms of anhydrous substance) - 250 mg

Excipient:

Water for injection - 1 ml

Description

Colorless transparent liquid.

Pharmacotherapeutic group

Nootropic remedy

ATX code

N07AX02

Pharmacodynamics:

Nootropic agent. Central anticholinergic stimulant, which contains 40.5% of metabolically protected choline. Metabolic protection promotes the release of choline in the brain.

Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system and activates the reticular formation. Increases the linear velocity of blood flow on the side of the traumatic brain injury contributes to the normalization of the spontaneous bioelectrical activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain (discirculatory encephalopathy and residual symptoms of cerebrovascular accident).

It has a preventive and corrective effect on the pathogenetic factors of the involutionary psychoorganic syndrome; it changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.

Stimulates dose-dependent release of acetylcholine under physiological conditions; participating in the synthesis of phosphatidylcholine (membrane phospholipid) improves synaptic transmission, plasticity of neuronal membranes, receptor function. Does not affect the reproductive cycle, does not have teratogenic and mutagenic effects.

Pharmacokinetics:

Absorption - 88%. Choline alfoscerate easily penetrates the blood-brain barrier.

It is excreted mainly by the lungs in the form of carbon dioxide (15%), as well as by the kidneys and through the intestines (15%).

Indications:

- Traumatic brain injury with a predominantly stem level of the lesion (acute period)

- cerebrovascular insufficiency

- psychoorganic syndrome against the background of degenerative diseases and involutional processes of the brain

- multi-infarction dementia.

Contraindications:

- Pregnancy breastfeeding

- hypersensitivity to drug components

- age up to 18 years

- hemorrhagic stroke (acute period).

Method of administration and dosage:

Intramuscularly or intravenously slowly at 1000 mg / day for 15-20 days.

For intravenous administration, the contents of one ampoule (4 ml) are diluted in saline.

Side effects:

Allergic reactions nausea.

Overdose:

Symptoms: nausea. Treatment: symptomatic.

Interaction:

No significant interaction with other drugs has been established.

Release form / dosage:

Solution for intravenous and intramuscular administration of 250 mg / ml.

Packaging:

In ampoules of neutral or light-shielding glass, 4 ml. 3 ampoules or 5 ampoules in a blister strip packaging. One blister strip packaging together with instructions for medical use in a cardboard box.

Storage conditions:

List B. In a dry, dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life:

5 years. Do not use after the expiration date.

Vacation conditions

On prescription